From September, 2017, WHO will accept applications for prequalification into their Essential Medicines List for biosimilar versions of two biologics: rituximab (for non-Hodgkin's lymphoma) and trastuzumab (for breast cancer). This pilot project is an effort to increase access to these costly cancer treatments in low-income countries.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r5yRh3
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background. Reconstruction of surgical defects following cranial base surgery is challenging. Others have demonstrated that leukocyte-platel...
-
During lytic infection, herpes simplex virus (HSV) DNA is replicated by a mechanism involving DNA recombination. For instance, replication o...
-
Outcomes of multimodal management for sinonasal squamous cell carcinoma. J Craniomaxillofac Surg. 2017 May 12;: Authors: Paré A, Blan...
-
Abstract Purpose Low back pain is a significant problem for school-aged athletes. Although some risk factors relating to sports activiti...
-
Thyroid cancer is the most common malignant tumor of the endocrine system and the incidence has been increasing in recent years. In a great ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου